Effect of Ubiquinone Administration on Stable Chronic Obstructive Pulmonary Disease
| Main Authors: | Imansyah, Budhi; Faculty of Medicine, University of Indonesia/ Persahabatan Hospital, Jakarta, Yunus, Faisal; Faculty of Medicine, University of Indonesia/ Persahabatan Hospital, Jakarta, Wiyono, Wiwien Heru; Faculty of Medicine, University of Indonesia/ Persahabatan Hospital, Jakarta |
|---|---|
| Format: | application/pdf eJournal |
| Bahasa: | eng |
| Terbitan: |
Journal of the Indonesian Medical Association
, 2008
|
| Online Access: |
http://indonesia.digitaljournals.org/index.php/idnmed/article/view/576 |
Daftar Isi:
- Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. Ubiquinone is contained in mitochondria and has an important role in aerobic energy production and metabolism. Administration of ubiquinone could improve the quality of life of patients with stable chronic obstructive pulmonary disease. A controlled randomized and double-blind clinical trial was performed with Patients were eligible if they were stable COPD as GOLD criteria, ages more than 30 years old. Patient were randomly assigned to receive ubiquinone or placebo for 12 weeks. Patients were instructed to continue other routine medication. All patients were assessed the level of lactate, lung function, blood gas analysis, six minute walking test and quality of life patient of COPD with St George’s Respiratory Questionnare (SGRQ) before and after 12 weeks of ubiquinone or placebo administration. A total 60 patients were available for outcome analysis, 30 patients in ubiquinone group and 30 patiens in control group. There were no differences between the groups with regard to gender, stage of COPD, BMI. The serum level of lactate was significantly decreased in an ubiquinone group compared to control group (1.10+1.1, -1.02+0.94; p<0.01). Lung function and blood gas analysis did not change in all subjects (p>0.05). There was significant increase in the distance of six minute walking test in ubiquinone group compared to control group (-35.78 ± 27.30, 0.21 ± 25.90; p<0.01). Patients who had received ubiquinone showed significant improvement of SGRQ score in symptoms, activity and impact compared to placebo (22.32 ± 9.10 vs -1.42+3.68; p<0.01, 2.95+2.87 vs -4.19+13.29;p<0.01, 15.37 ± 8.43 vs -2.25+8.21;p<0.01). Ubiquinone administration has favorable effect on the energy production of muscle in patients with stable COPD and on improvement of quality of life.Keywords: ubiqinone, COPD, level of lactate, SGRQ, quality of life